Louise Frederika Kooij Sells 40,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $30.20, for a total value of $1,208,000.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $735,460.60. This represents a 62.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00.

NewAmsterdam Pharma Stock Up 3.8%

Shares of NASDAQ NAMS traded up $1.21 during trading hours on Wednesday, hitting $32.60. The company had a trading volume of 1,235,979 shares, compared to its average volume of 1,027,622. NewAmsterdam Pharma Company N.V. has a 1-year low of $17.67 and a 1-year high of $42.21. The firm’s 50 day moving average is $32.94 and its 200-day moving average is $33.19. The stock has a market capitalization of $3.81 billion, a P/E ratio of -18.22 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The firm had revenue of $3.04 million for the quarter. On average, sell-side analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its stake in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. KBC Group NV bought a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at $37,000. Navalign LLC acquired a new position in shares of NewAmsterdam Pharma during the 4th quarter worth $46,000. Finally, AdvisorNet Financial Inc acquired a new position in shares of NewAmsterdam Pharma during the 1st quarter worth $82,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Finally, Truist Financial started coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and an average price target of $48.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.